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Abstract The field of myocardial regeneration utilizing
novel cell-based therapies, gene transfer, and growth factors
may prove to play an important role in the future
management of ischemic heart disease and cardiomyopathy.
Phases I and II clinical trials have been published for a
variety of biologics utilizing four methods of delivery:
systemic infusion, intracoronary infusion, transvenous coro-
nary sinus, and intramyocardial. This review discusses the
advantages and disadvantages of the delivery approaches
above.
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Despite advances in prevention and treatment, coronary
heart disease (CHD) is still the leading cause of morbidity
and mortality. More than 1.26 million Americans were
diagnosed with CHD in 2006, and one million suffered
myocardial infarctions (MI). Only one third of these
patients experience a full recovery and over 550,000
develop congestive heart failure. The direct and indirect
costs of CHD are estimated to be $177.1 billion for 2010
[1]. Although current treatment options, such as pharma-
cological therapies and revascularization procedures have
achieved important advances, these treatments are not
always completely effective. In addition, there are currently
no treatments to restore permanently damaged myocardium.
The field of myocardial regeneration (angiogenesis and
myogenesis) might prove to play an important role in the
future management of patients who suffer the effects of
myocardial ischemia and injury.
The delivery methods identified are used to deliver
biologics such as stem cells or other therapeutic substances
to the vascular system or directly into the myocardium and
can be administered via different routes. The four major
techniques for stem cell administration that will be
addressed include (1) intramyocardial which include epi-
cardial and transendocardial; (2) intracoronary; (3) trans-
venous coronary sinus; and (4) intravenous. Variations
within each approach have been developed to solve issues
of safety, feasibility, cell viability, and retention. The
following is a summary of each anatomical approach and
an analysis of the pros and cons of various methods within
each of them [2].
A report published by the International Society for
Cardiovascular Translational Research published recom-
mendations for the criteria for training on these methods of
delivery, Dib et al. and describes some important key
elements [2].
These therapies remain in the early stages of develop-
ment and implementation. As a result, significant questions
persist regarding the safest and most efficacious approach.
Issues of cell type, dose, distribution, retention, and method
of administration for various indications have been
explored extensively [3–8]. A limitation of cell therapy or
other biologics for cardiac regeneration is that these
substances when injected directly into the myocardium are
capable of entering the vasculature and migrating to remote
organs [3]. Hou et al. [3] demonstrated retention rates
within the heart of 11% intramyocardial (IM), 3% intra-
coronary (IC), and 3% intravenous (IV). Significant
numbers of cells are trapped in the lungs—47% (IC), 26%
(IM), 43% (IV)—and lesser numbers travel to the liver,
spleen, and kidneys.
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Intramyocardial Administration
IM administration involves injection of therapeutic agents
directly into the myocardium. Injections are most frequently
made into the left ventricle by a direct epicardial approach
or using a catheter-based transendocardial approach.
Epicardial injection is considered the most reliable
method of delivery, which also results in higher cell
retention within the myocardium [2, 3, 9–11]. In previous
clinical trials of epicardial injection, cell transplant was
performed using a minimally invasive surgical approach via
a left anterior mini-thoracotomy [12] or combined with
coronary artery bypass graft or other open heart procedures
[9–11]. Surgical exposure of the heart provides direct
access and visualization of the epicardium. Location of
the injection sites are identified prior to surgery using non-
invasive methods including nuclear imaging and echocar-
diography. During surgery, injection sites are located by
direct visualization and therapy is administered to the
external surface of the heart via a standard syringe.
Injections can be made into a beating or arrested heart.
Drawbacks to this procedure include its invasive nature.
This procedure also limits access to certain areas of the left
ventricle such as the septum. There is also a risk of
perforation at the injection sites inside the left ventricle
(LV), as well as systemic embolization. Tissue inflamma-
tion may also increase the risk of cardiac arrhythmias or
require the use of corticosteroids or other anti-arrhythmic
agents [2, 13].
Transendocardial injection utilizes a percutaneous
catheter-based approach. There are varieties of catheters
currently undergoing Phases I and II clinical trials which
use either a fluoroscopic 2-dimensional (2D) guidance
system or a 3-dimensional (3D) system. The Helix™
infusion catheter (BioCardia, Inc., South San Francisco,
CA) and the MyoCath™(Bioheart Inc., Sunrise, FL), are
2D systems. The Myostar™ Injection Catheter is combined
with a 3D guidance system NOGA® XP (Biologics
Delivery Systems, Diamond Bar, CA) [4–6, 14, 15].
Unlike the surgical method, this procedure can be
extended to the high-risk population and be repeated if
needed. Preclinical evidence indicates that this approach
achieves better myocardial cell retention when compared to
intravascular infusion possibly resulting in greater thera-
peutic effects [3, 12]. The 3D-guided system also avoids
local toxicity by distributing the injections across the infarct
area, border area of the infarct, and ischemic area. As with
all forms of endocardial injection, the risk of perforation,
tissue irritation, and arrhythmia still remains.
BioCardia's Helical Infusion Catheter is a catheter with a
small, hollow, distal corkscrew needle, which is rotated into
tissue to provide active fixation during drug delivery
similar to the active fixation electrodes used in cardiac
pacing [16]. This system provides a means for fixation to
the beating heart wall, uses fluoroscopic imaging, crosses
the aortic arch and valve over a guide wire with BioCardia's
Morph® Deflectable steerable guide, and allows 3° of
freedom to maximize operator control. The Morph®
Deflectable Guide Catheter can be used to steer a guide
wire through the aortic valve for transendocardial delivery
from within the LV. For transendocardial delivery, the
Morph® Deflectable Guide Catheter is advanced over the
wire, and the wire is removed to allow for advancement and
navigation of the Helical Infusion Catheter [4–6]. This
catheter is under investigational use in multiple ongoing
clinical trials [4–6, 14].
The MyoCath™ system utilizes a 115-cm-long deflect-
able injection catheter that contains a single core 25-gauge
needle which is advanced and retracted from the tip of the
catheter and provides for multiple injections to a pre-
determined needle insertion depth [7].
The Myostar™ is a steerable catheter equipped with a
location sensor and a retractable, hollow 27-gauge
needle. The catheter interfaces with the NOGA® 3D
electromagnetic cardiac mapping system for local agent
delivery into the myocardium [17]. The NOGA® map is a
3D reconstruction of the LV from electromechanical points
obtained by the mapping catheter. The NOGA® map
discriminates between areas of MI, the border zone of the
MI, and normal myocardium [18]. The precise areas
intended for injection can be identified when used in
combination with imaging techniques such as echocardi-
ography to measure wall thickness and single-photon
emission computed tomography to assess myocardial
perfusion [19]. This information provides increased accu-
racy and homogeneous distribution of injections [8, 15,
17, 20–22].
Intracoronary Administration
Intracoronary administration is the preferred technique
following acute myocardial infarction and has been previ-
ously described extensively [2, 23–26]. Similar to balloon
angioplasty, treatments commonly performed for coronary
artery occlusions, IC transfer is the most practiced
technique of coronary cell transfer. Cells are injected
through the delivery catheter at slow or high flow rates
while maintaining coronary flow (non-occlusive) or inter-
rupting it with balloon occlusion (“stop-flow” method) [2].
In the case of non-occlusive angioplasty method, a balloon
catheter or specialty catheters are used for the sub-selective
injection in the coronary vessel. “Stop-flow” method uses a
temporary balloon inflation to reduce cell loss due to speed
of blood flow. New techniques and devices are currently
being developed and tested [2].
178 J. of Cardiovasc. Trans. Res. (2011) 4:177–181
Potential advantages may include homogenous distribu-
tion of the cells in the targeted myocardium and can be
applied in studies for chronic myocardial ischemia or
ischemic LV dysfunction [2]. This procedure requires cell
migration which is partially guided by a phenomenon called
stem cell homing. Cells migrate preferentially toward
damaged myocardium and retention is largely dependent
on adhesion to the endothelial layer of the vasculature
[2, 23–27].
Issues to consider regarding this method include post-
infusion blood flow in the target artery, timing of cell
delivery, type of cell and cell preparation. Total occlusion
of the coronary artery from the balloon inflation may lead
to decreased blood flow which could cause ischemia
leading to arrhythmia. The movement of large cells or
particularly viscous suspensions may pose risk of occlusion
or emboli which may also reduce accuracy of targeting and
retention [24, 28]. This method is also unsuitable when
inflow arteries are occluded [12].
Retrograde Coronary Sinus Delivery
The coronary sinus (CS) and coronary veins have been
utilized in applications for several therapeutic interventions.
The retrograde coronary sinus delivery method provides
access to the target ischemic and infarcted regions of the
heart. Details of this procedure have been previously
described [2, 26, 29, 30]. A small number of preclinical
and early clinical studies demonstrated safety and feasibil-
ity of delivering stem cells via the coronary sinus. Coronary
sinus delivery is the preferred option in cases of severe
subtotal stenosis of one or more coronary arteries or severe
aortic stenosis. This approach provides safe and accurate
access to most of the myocardium creating more homog-
enous delivery [2].
Potential limitations and complications of this technique
include variability in coronary sinus anatomy and coronary
sinus rupture. Access to CS will not be available in heart failure
patients with resynchronization devices. Issues to consider
regarding this method include the type of cell or cell
preparation. The movement of large cells or particularly
viscous suspensions may pose risk of occlusion or emboli.
Also important is the effectiveness of cell homing. There is
insufficient evidence to determine whether or not homing is
effective with all forms of heart damage including chronic
disease or remodeling as a result of previousMI [2, 26, 29, 30].
Intravenous Administration
Systemic stem cell delivery is very low risk and utilizes a
standard intravenous infusion. It is the easiest to administer
and the least invasive route of delivery. This delivery
method depends heavily stem cell homing signals to the
area of injury following an acute myocardial infarction.
Preclinical studies indicate low cell retention within the
heart following IV infusion and that a significant number
are trapped in the lungs [31].
Conclusion
Biological therapeutics can be delivered utilizing several
approaches. Intramyocardial, epicardial, and transendo-
cardial delivery approaches are shown to be accurate and
reliable. The epicardial approach provides direct visual-
ization of the heart allowing for more accurate adminis-
tration, but is high risk due to its invasive nature.
Transendocardial methods that utilize the 3D mapping
systems provide increased accuracy. The potential for
perforating the myocardium poses the most serious risk
for these approaches. The intracoronary method is
preferred post-acute MI and is similar to balloon
angioplasty, a commonly performed procedure. It is
dependent on cell retention and additional factors such
as timing of delivery, cell adhesion and homing.
Coronary sinus delivery is considered lower risk and is
a potentially effective method. Limitations of this
procedure include the variability in coronary sinus
anatomy and risk of coronary sinus rupture. Intravenous
biologics delivery is the easiest and least invasive of all
discussed methods, but relies heavily on cell homing.
Optimizing the safety and accuracy of these procedures
by establishing training guidelines can significantly affect
the outcomes of these therapies. Initial recommendations
have been published for training on these methods of
delivery by the Task Force for the International Society for
Cardiovascular Translational Research [2].
Controversies and challenges that still remain in the
field of cell-based therapies include optimal cell type,
delivery route, timing, therapeutic dose, cell survival and
retention. Current preclinical investigations aimed at
enhancing cell survival and retention includes genetic
modifications, combining stem cells with gene products
or biomaterials such as collagen matrix [32]. Ongoing
and future clinical studies can address these challenges
through randomized, double-blind, placebo-controlled
study designs [33, 34].
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